---
layout: post
title: "Prospective Grant of an Exclusive Patent License: The Development of Natural Killer (NK) Cell Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) T Cell Receptor (TCR) Therapy for the Treatment of KK-LC-1 Expressing Human Cancers"
date: 2026-02-05 19:09:00 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-06475
original_published: 2021-03-30 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: The Development of Natural Killer (NK) Cell Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) T Cell Receptor (TCR) Therapy for the Treatment of KK-LC-1 Expressing Human Cancers

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** March 30, 2021 00:00 UTC
**Document Number:** 2021-06475

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice Zelluna Immunotherapy (Zelluna), located in Oslo, Norway.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/30/2021-06475/prospective-grant-of-an-exclusive-patent-license-the-development-of-natural-killer-nk-cell)
- API: https://www.federalregister.gov/api/v1/documents/2021-06475

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
